Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis
Clinical Nutrition · 2025-12 · 55 · 42-56
DOI: 10.1016/j.clnu.2025.10.006 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Nutrition, 2025-12. Verfasst von Wenjie Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China; Institute of Clinical Pharmacy, Cen…. Hauptthemen laut MEDLINE: Sarcopenia, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIMS: GLP-1 receptor agonists (GLP-1RAs) are first-line therapies for type 2 diabetes (T2DM) due to their additional weight-lowering and cardiovascular benefits. However, their impact on muscle mass is debated, posing a concern for sarcopenia in older adults with T2DM. This systematic review and meta-analysis aimed to evaluate the effects of GLP-1RAs on body composition and sarcopenia-related markers in diabetic patients and relevant preclinical models, and to explore the underlying mechanisms. METHODS: We systematically searched PubMed, Web of Science, MEDLINE, Cochrane Library, and EMBASE to identify relevant randomized controlled trials and animal studies on the impact of GLP-1 RAs on muscle in diabetic participants. Standardized Mean Difference (SMD) or Mean Difference (MD) with 95 % confidence intervals (CI) were calculated using random-effects or fixed-effect models to synthesize the effects on anthropometric, functional, and molecular endpoints. RESULTS: A total of 254 articles were retrieved, yielding 18 eligible studies after screening against the inclusion criteria. These comprised six human studies measuring lean mass, four clinical trials assessing Skeletal Muscle Mass Index (SMI), and eight animal studies. The animal studies investigated parameters including muscle mass, muscle fiber cross-sectional area, grip strength, lean mass percentage, myogenin, MyoD, Atrogin-1, MuRF-1, myostatin, GLUT4, SIRT1, and inflammatory cytokines (IL-1β, IL-6, TNF-α). CONCLUSIONS: GLP-1 RAs were found to increase the percentage of lean body mass in animal models, improve body composition, enhance skeletal muscle strength, elevate concentrations of muscle growth factors, and reduce muscle growth inhibitory factors and inflammatory factors. These effects promote muscle cell proliferation and differentiation, accelerate muscle protein synthesis, leading to better overall muscle function. Confirming these promising preclinical findings requires large-scale randomized controlled trials in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China; Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, 410011, PR China.
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, PR China.
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011,…
- Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, PR China.
- Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China.
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, PR China.
Förderung
- Hunan Provincial Natural Science Foundation
Zitieren
APA
Chen, W., Qin, H., Zhou, Z., Chen, Y., Xu, X., Chen, Y., He, J., Xu, R., Gao, H., & Lu, Q. (2025). Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis. Clinical Nutrition, 55, 42-56. https://doi.org/10.1016/j.clnu.2025.10.006
Vancouver
Chen W, Qin H, Zhou Z, Chen Y, Xu X, Chen Y, et al. Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis. Clinical Nutrition. 2025;55:42-56. doi:10.1016/j.clnu.2025.10.006
BibTeX
@article{Chen2025,
author = {Chen, Wenjie and Qin, Hongzhuo and Zhou, Zhaokai and Chen, Yun and Xu, Xiaowei and Chen, Yajun and He, Jieyu and Xu, Ran and Gao, Hua and Lu, Qiong},
title = {Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis},
journal = {Clinical Nutrition},
year = {2025},
volume = {55},
pages = {42--56},
doi = {10.1016/j.clnu.2025.10.006}
}
EUVIMED